|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||5.25 - 5.48|
|52 Week Range||1.45 - 9.40|
|PE Ratio (TTM)||-5.46|
|Earnings Date||Nov 6, 2017 - Nov 10, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||17.50|
Conatus' (CNAT) efforts to develop lead candidate emricasan in absence of an approved product in the company's portfolio are a positive step toward driving growth.
David Stemerman is winding down his hedge fund firm to explore a run for governor of Connecticut, according to a letter sent to clients of Conatus Capital Management LP on Tuesday. "Connecticut – home to my family and business – is in crisis," Stemerman wrote in the note, which was viewed by Reuters. The next election for governor in Connecticut is in November 2018.
Conatus (CNAT) reported earnings more than a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
SAN DIEGO, Aug. 31, 2017-- Conatus Pharmaceuticals Inc., a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced the appointment ...
SAN DIEGO, Aug. 29, 2017-- Conatus Pharmaceuticals Inc. today announced its scheduled presentation to provide an overview of the company’ s programs and outlook at the Rodman & Renshaw 19 th Annual Global ...
Conatus's (CNAT) efforts to develop lead candidate emricasan in absence of an approved product in its portfolio are a positive step by the company to propel growth.
SAN DIEGO, Aug. 14, 2017-- Conatus Pharmaceuticals Inc. today announced the completion of enrollment in ENCORE-NF, a randomized, double-blind, placebo-controlled, Phase 2 b clinical trial evaluating emricasan, ...
Conatus (CNAT) reports wider-than-expected loss in Q2. However, revenue beat estimates, courtesy higher collaboration benefits.
On a per-share basis, the San Diego-based company said it had a loss of 19 cents. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
SAN DIEGO, Aug. 02, 2017-- Conatus Pharmaceuticals Inc., a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced financial results ...
NEW YORK, NY / ACCESSWIRE / August 2, 2017 / Conatus Pharmaceuticals Inc. (NASDAQ: CNAT ) will be discussing their earnings results in their Q2 Earnings Call to be held on Wednesday, August 2, 2017 at ...
SAN DIEGO, July 26, 2017-- Conatus Pharmaceuticals Inc. today announced that it will report financial results for the second quarter ended June 30, 2017, after the market close on Wednesday, August 2, ...
Conatus' (CNAT) aim to progress with its lead candidate emricasan might boost the stock in Q2 results, although the company's current portfolio shows no approved product and revenue generation.
Conatus Pharmaceuticals saw its shares make a handy gain on Friday after the firm announced an exclusive license agreement with Novartis.
On Monday, Conatus Pharmaceuticals Inc (NASDAQ:CNAT) announced that the FDA has granted Orphan Drug Designation to the company's drug candidate IDN-7314, for the treatment of primary sclerosing cholangitis (PSC).
Conatus Pharmaceuticals Inc. (CNAT) announced FDA's grant of Orphan Drug Designation (ODD) to its pipeline candidate IDN-7314 for treatment of primary sclerosing cholangitis.
NEW YORK, NY / ACCESSWIRE / June 27, 2017 / Moleculin Biotech and Conatus Pharmaceuticals were big winners on the NASDAQ yesterday. Moleculin in particular was a huge gainer scoring almost 40% in gains ...
Conatus (CNAT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
NEW YORK, NY / ACCESSWIRE / May 12, 2017 / Conatus shares took a mean dive after the company disclosed a public offering of its stock at $5.50 per share. Sangamo Therapeutics on the other hand climbed ...